28.49 USD
↗ 0.75 (2.70%)AT CLOSE (11:59 AM EDT)
Arcutis Biotherapeutics, Inc. Common Stock
ARQTNASDAQ • USD
28.15
↘ 0.34 (1.19%)
POST MARKET (AS OF 05:40 PM EDT)
Post Market
AS OF 05:40 PM EDT
28.15
↘ 0.34 (1.19%)
Market: CLOSED
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is currently trading at $28.49. Our models show a "Strong Buy" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, ARQT is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jul 17, 2026.
Open?$27.49
High?$28.87
Low?$27.43
Prev. Close?$27.74
Volume?1.3M
Avg. Volume?1.8M
VWAP?$28.42
Rel. Volume?0.72x
Bid / Ask
Bid?$27.98 × 100
Ask?$29.00 × 100
Spread?$1.02
Midpoint?$28.49
Valuation & Ratios
Market Cap?3.6B
Shares Out?125.1M
Float?109.3M
Float %?89.3%
P/E Ratio?N/A
P/B Ratio?18.79
EPS?-$0.02
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Address
3027 TOWNSGATE ROAD
WESTLAKE VILLAGE, CA 91361
Phone: 805-418-5006
WESTLAKE VILLAGE, CA 91361
Phone: 805-418-5006
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?100
Momentum?97
Short Sent.?59
Piotroski F-Score?4/9Mixed
Altman Z-Score?6.05Safe
Confidence?63%Moderate
Short InterestHigh
Short % of Float?12.82%High
Short Interest?14.0M
Days to Cover?6.3
Free Float109.3M
Avg Daily Volume2.2M
Settlement Date2026-06-30
Financial Health
Current Ratio?2.68Strong
Quick Ratio?2.45Strong
Cash Ratio?0.21Low
Debt/Equity?0.58Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?18.79HIGH▾
Peers100
S&P8
P/S?8.57HIGH▾
Peers100
S&P11
P/FCF?132.4PRICEY▾
Peers100
S&P3
EV/EBITDA?766.4HIGH▾
Peers100
S&P3
EV/Sales?8.75HIGH▾
Peers100
S&P14
Returns & Efficiency
ROE?-1.3%WEAK▾
S&P14
ROA?-0.5%WEAK▾
S&P6
Cash Flow & Enterprise
FCF?$26.9M
Enterprise Value?$3.6B
Fundamentals ratios updated end of day